José M Porcel1,2, Cristina Solé3, Antonieta Salud4,5, Silvia Bielsa3,4. 1. Pleural Medicine Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, Avda Alcalde Rovira Roure 80, 25198, Lleida, Spain. jporcelp@yahoo.es. 2. Institute for Biomedical Research Dr Pifarre Foundation, IRBLLEIDA, Lleida, Spain. jporcelp@yahoo.es. 3. Pleural Medicine Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, Avda Alcalde Rovira Roure 80, 25198, Lleida, Spain. 4. Institute for Biomedical Research Dr Pifarre Foundation, IRBLLEIDA, Lleida, Spain. 5. Department of Medical Oncology, Arnau de Vilanova University Hospital, Lleida, Spain.
Abstract
PURPOSE: Malignant pleural effusions (MPE) may either coincide with or follow the diagnosis of a primary tumor. Whether this circumstance influences prognosis has not been well substantiated. METHODS: Retrospective review of all consecutive patients who were cared for at a Spanish university hospital during an 11-year period and received a diagnosis of MPE. RESULTS: Of 401 patients, the MPE was the first evidence of cancer in 265 (66%), and it followed a previously diagnosed neoplasm in 136 (34%). Lung cancer predominated in the former group (131, 50%), and breast cancer in the latter (55, 40%). MPE that were the presenting manifestation of hematological and ovarian tumors had a statistically significant survival advantage as compared to those which developed in patients from a previously known cancer (respective absolute differences of 41 and 20 months; p < 0.005). CONCLUSIONS: In hematological and ovarian malignancies, the synchronous or metachronous diagnosis of MPE may have prognostic implications.
PURPOSE:Malignant pleural effusions (MPE) may either coincide with or follow the diagnosis of a primary tumor. Whether this circumstance influences prognosis has not been well substantiated. METHODS: Retrospective review of all consecutive patients who were cared for at a Spanish university hospital during an 11-year period and received a diagnosis of MPE. RESULTS: Of 401 patients, the MPE was the first evidence of cancer in 265 (66%), and it followed a previously diagnosed neoplasm in 136 (34%). Lung cancer predominated in the former group (131, 50%), and breast cancer in the latter (55, 40%). MPE that were the presenting manifestation of hematological and ovarian tumors had a statistically significant survival advantage as compared to those which developed in patients from a previously known cancer (respective absolute differences of 41 and 20 months; p < 0.005). CONCLUSIONS: In hematological and ovarian malignancies, the synchronous or metachronous diagnosis of MPE may have prognostic implications.
Authors: Edward T H Fysh; Silvia Bielsa; Charley A Budgeon; Catherine A Read; Jose M Porcel; Nick A Maskell; Y C Gary Lee Journal: Chest Date: 2015-06 Impact factor: 9.410
Authors: Amelia O Clive; Brennan C Kahan; Clare E Hooper; Rahul Bhatnagar; Anna J Morley; Natalie Zahan-Evans; Oliver J Bintcliffe; Rogier C Boshuizen; Edward T H Fysh; Claire L Tobin; Andrew R L Medford; John E Harvey; Michel M van den Heuvel; Y C Gary Lee; Nick A Maskell Journal: Thorax Date: 2014-08-06 Impact factor: 9.139